Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Carbon Nanoparticle Labelled Node Biopsy in Breast Cancer
NCT04482803Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Open-label, single-arm trial of Kanarine in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Accuracy of carbon nanoparticle labelled lymph nodes in predicting axillary lymph nodes. Started Sep 2020; status: completed.
02
Drugs
Kanarine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04482803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482803.